A recently approved injectable eczema drug provides quick itch relief to patients with the maddening skin disease, a new ...

--New results show Eli Lilly and Company's EBGLYSS achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis at three years. These findings from the ADjoin long-term ...

Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significantly improved overall disease severity and significantly reduced itch compared to TCS alone ...

Sanofi ($SNYNF) announced an update on their ongoing clinical study. Sanofi’s recent clinical study, officially titled ‘A Phase 3, Randomized, ...

TARRYTOWN, N.Y. and PARIS, June 28, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency will update the Dupixent® ...

Atopic dermatitis’ (AD) deeper complexities were exposed in 2025. Once seen mainly as a visible skin condition, AD is now widely recognized as a long-lasting inflammatory disease that affects sleep, ...

EBGLYSS is an interleukin-13 (IL-13) inhibitor that selectively blocks IL-13 signaling with high binding affinity. 2,3,4 The cytokine IL-13 is a primary cytokine in atopic dermatitis, driving the type ...

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis ...

Among EBGLYSS Week 16 responders from the monotherapy trials, 50% achieved highest bar of complete skin clearance (EASI 100 or IGA 0) and 87% achieved almost-clear skin (EASI 90) at three years with ...